Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Immunoglobulin Light-chain Amyloidosis 1Endometrial Neoplasms 1Classic Follicular Lymphoma 1Amyloidosis 1

Interventions

Rituximab 39Cyclophosphamide 35Magnetic Resonance Spectroscopy 22Specimen Handling 20Doxorubicin 18polatuzumab vedotin 17Prednisone 17Lenalidomide 15Biopsy 15fludarabine 13Oxaliplatin 13Gemcitabine 13zanubrutinib 11Vincristine 11Immunotherapy, Adoptive 10Etoposide 10glofitamab 9axicabtagene ciloleucel 7Prednisolone 7obinutuzumab 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Leukapheresis 6Injections 6Ifosfamide 6Bendamustine Hydrochloride 6loncastuximab tesirine 5ibrutinib 5acalabrutinib 5Carboplatin 5CT-P10 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lymphoma, Large B-Cell, Diffuse × Hyaluronoglucosaminidase × Clear all
NCT05455697 2025-12-18

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

University of Washington

Phase 1/2 Recruiting
35 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡